Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil? Curr Gastroenterol Rep 2018 Aug 04;20(9):40
Date
08/06/2018Pubmed ID
30078085DOI
10.1007/s11894-018-0647-4Scopus ID
2-s2.0-85051140000 (requires institutional sign-in at Scopus site) 12 CitationsAbstract
PURPOSE OF THE REVIEW: Fish oil (FO) supplementation has historically been used by individuals suffering from cardiovascular disease and other inflammatory processes. However, a meta-analysis of several large randomized control trials (RCTs) suggested FO conferred no benefit in reducing cardiovascular risk. Skeptics surmised that the lack of benefit was related to FO dose or drug interactions; therefore, the widely accepted practice of FO consumption was brought into question.
RECENT FINDINGS: Thereafter, Serhan et al. identified specialized pro-resolving mediators (SPMs) to be one of the bioactive components and mechanisms of action of FO. SPMs are thought to enhance resolution of inflammation, as opposed to classic anti-inflammatory agents which inhibit inflammatory pathways. Numerous diseases, including persistent Inflammation, immunosuppression, and catabolic syndrome (PICS), are rooted in a burden of chronic inflammation. SPMs are gaining traction as potential therapeutic agents used to resolve inflammation in cardiovascular disorders, inflammatory bowel disease, sepsis, pancreatitis, and acute respiratory distress syndrome (ARDS). This narrative reviews the history of FO and the various studies that made the health benefits of FO inconclusive, as well as an overview of SPMs and their use in specific disease states.
Author List
Rosenthal MD, Patel J, Staton K, Martindale RG, Moore FA, Upchurch GR JrAuthor
Jayshil Patel MD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Cardiovascular DiseasesFish Oils
Humans
Inflammation
Inflammation Mediators
